Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead

Oct 16 2009

• By The Pink Sheet Daily

Related Content

FDA Advisors Question Impact of OxyContin Improvements Due To Generics

Oct 05 2009

FDA Panel Okays Purdue's Newer OxyContin, But Is Still Hung Up On Safety

Sep 24 2009

Chew On This: FDA OK's King's Tamper-Resistant Morphine, Embeda

Aug 13 2009

REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely

Jun 08 2009

Joint Advisory Committee Says Exalgo Should Have Phased-In Entry To Market

Sep 23 2009

Exalgo Joint Advisory Committee Will Compare Risks To Other Opioids

Sep 22 2009

Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA

Jul 20 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window